PMN ProMIS: Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan

This daily price chart for ProMIS Neurosciences (PMN) reflects an EV/EBITDA ratio of 0.00. ProMIS Neurosciences develops specific antibodies to combat dementia, generating sustainable solvent demand over the long term. Its high-tech production is based on a selective approach to neuron therapy. Authoritative management ensures the success of the business model by effectively advancing innovative developments through the stages of clinical trials.

PMN ProMIS Neurosciences Inc.: Nilai bisnis marang bathi operasional sadurunge panyusutan ing interval 23.11.2025 - 10.11.2026

promisneurosciences.com (PMN) - rincian metrik lan laporan keuangan

- rega saiki lan proyeksi nilai saham:

Rega saham ProMIS Neurosciences, Inc.|PMN - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Biji pasar ProMIS Neurosciences, Inc.|PMN - Nilai Perusahaan

- rincian valuasi buku bisnis:

Aset Bersih saben Siji Saham ProMIS Neurosciences|PMN - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku promisneurosciences.com|PMN - Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

Utang marang Ekuitas ProMIS Neurosciences|PMN - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas ProMIS Neurosciences, Inc.|PMN - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku ProMIS Neurosciences, Inc.|PMN - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan ProMIS Neurosciences|Likuiditas cepet promisneurosciences.com

- data bathi bisnis lan rasio investasi:

PMN - Bathi sawise pajeg|Bathi sing dikarepake ProMIS Neurosciences|PMN - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep ProMIS Neurosciences, Inc.|PMN - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan ProMIS Neurosciences, Inc.|PMN - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) ProMIS Neurosciences|PMN - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan promisneurosciences.com|PMN - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep ProMIS Neurosciences

Analisis wiwitan perusahaan:ProMIS PMN

Scaling the expansion of PMN310 antibodies requires significant capital expenditures; therefore, the EV/EBITDA multiple history of the business allows for an objective valuation of ProMIS Neurosciences (PMN) assets, accounting for the debt load. This indicator compares total market capitalization and loans against operating profit before taxes, helping investors identify excessive leverage risks and determine the issuer's financial stability.

Pesaing utama